# Topotecan Hydrochloride and Doxorubicin Hydrochloride in Treating Relapsed or Refractory Small Cell Lung Cancer

> **NCT00856037** · PHASE1 · COMPLETED · sponsor: **University of Nebraska** · enrollment: 22 (actual)

## Conditions studied

- Recurrent Small Cell Lung Carcinoma

## Interventions

- **DRUG:** Doxorubicin Hydrochloride
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Quality-of-Life Assessment
- **DRUG:** Topotecan Hydrochloride

## Key facts

- **NCT ID:** NCT00856037
- **Lead sponsor:** University of Nebraska
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02-02
- **Primary completion:** 2018-02-01
- **Final completion:** 2018-02-01
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2023-09-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00856037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00856037, "Topotecan Hydrochloride and Doxorubicin Hydrochloride in Treating Relapsed or Refractory Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00856037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*